Skip to main content

Advertisement

Table 1 LSD1 inhibitory (IC50, μM) and antiproliferative (15-day treatment EC50, μM) activities for compounds 14

From: Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia

  LSD1 IC50 MLL-rearranged leukemia Non-MLL leukemia cells Breast Prostate
MV4-11 Molm-13 NB4 U937 MCF-7 LNCaP
1 0.0098 0.010 0.096 19.4 18.9 1.6 3.7
2 0.077 0.084 0.32 18.9 34.6 6.6 10.0
3 0.035 0.020 0.18 >50 >50 13.5 29.9
4 5.3 1.4 12 >50 17.5 >50 >50